1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,288 | 0,302 | 10:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.09. | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 199 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08. | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 270 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 28.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 18.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| 12.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025 | 2 | HKEx | ||
| 04.06. | VIVA BIOTECH (01873): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION | - | HKEx | ||
| 30.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.05. | VIVA BIOTECH (01873): CONNECTED TRANSACTION INVESTMENT IN LIMITED PARTNERSHIP FUND | 1 | HKEx | ||
| 15.05. | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 326 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 06.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ANNUAL REPORT | - | HKEx | ||
| 07.04. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 352 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 158 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
| 27.03. | VIVA BIOTECH (01873): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,812 | -0,31 % | UNGLAUBLICHE Sondermeldung bei Valneva Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| NOVONESIS | 53,70 | -0,78 % | Novonesis (Novozymes A/S): Major shareholder announcement | ||
| GENMAB | 239,40 | +0,29 % | Genmab: Die Dänen kommen! | Die Biotechnologiebranche befindet sich in einem dynamischen Wandel, geprägt von rasantem Fortschritt und steigendem Wettbewerbsdruck. Die dänische Genmab gehört dabei zu den Unternehmen, die mit wissenschaftlicher... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,728 | -3,32 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| BEONE MEDICINES LTD ADR | 280,00 | -0,71 % | BEIGENE (06160): SHARE PURCHASE PURSUANT TO THE EMPLOYEE SHARE PURCHASE PLAN | ||
| SINO BIOPHARM | 0,924 | -2,41 % | Aktie von Sino Biopharmaceutical heute am Aktienmarkt gefragt (0,9556 €) | Das Wertpapier von Sino Biopharmaceutical notiert am Freitag fester. Der jüngste Kurs betrug 0,96 Euro. An der Börse liegt die Sino Biopharmaceutical-Aktie derzeit im Plus. Das Wertpapier legte um 0... ► Artikel lesen | |
| VERICEL | 27,200 | +1,49 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| SENSEI BIOTHERAPEUTICS | 8,740 | 0,00 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,374 | 0,00 % | MustGrow Biologics Corp.: MustGrow Secures $2 Million Line of Credit with CIBC; Guaranteed by EDC | Saskatoon, Saskatchewan--(Newsfile Corp. - September 10, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce it has secured... ► Artikel lesen | |
| ZAI LAB LTD ADR | 27,200 | 0,00 % | Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback | ||
| BIOXCEL THERAPEUTICS | 2,615 | -3,15 % | BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia | BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p Complete resolution of agitation was significantly higher... ► Artikel lesen | |
| REGENXBIO | 7,800 | +0,65 % | REGENXBIO Inc.: REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE Trial of RGX-121 for Treatment of MPS II | 12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II
>80% reduction in CSF levels... ► Artikel lesen | |
| AKEBIA | 2,532 | +1,85 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 1,040 | -7,96 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE TO SHOWCASE CS2015 (OX40L/TSLP BISPECIFIC ANTIBODY) AT ACAAI 2025 |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.